Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series

Erica Brivio, Christophe F. Chantrain, Tanja A. Gruber, Adriana Thano, Fanny Rialland, Audrey Contet, Sarah Elitzur, Luciano Dalla-Pozza, Krisztián Miklós Kállay, Chi kong Li, Motohiro Kato, Inna Markova, Kjeld Schmiegelow, Nicole Bodmer, Erin H. Breese, Raoull Hoogendijk, Rob Pieters, Christian Michel Zwaan

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

9 Citaten (Scopus)

Samenvatting

No data on inotuzumab ozogamicin (InO) in infant acute lymphoblastic leukaemia (ALL) have been published to date. We collected data internationally on infants/young children (<3 years) with ALL treated with InO. Fifteen patients (median 4.4 months at diagnosis) received InO due to relapsed or refractory (R/R) disease. Median percentage of CD22+ blasts was 72% (range 40–100%, n = 9). The median dose in the first course was 1.74 mg/m2 (fractionated). Seven patients (47%) achieved complete remission; one additional minimal residual disease (MRD)-positive patient became MRD-negative. Six-month overall survival was 47% (95% confidence interval [CI] 27–80%). Two patients developed veno-occlusive disease after transplant. Further evaluation of InO in this subgroup of ALL is justified.

Originele taal-2Engels
Pagina's (van-tot)1172-1177
Aantal pagina's6
TijdschriftBritish Journal of Haematology
Volume193
Nummer van het tijdschrift6
DOI's
StatusGepubliceerd - jun. 2021

Vingerafdruk

Duik in de onderzoeksthema's van 'Inotuzumab ozogamicin in infants and young children with relapsed or refractory acute lymphoblastic leukaemia: a case series'. Samen vormen ze een unieke vingerafdruk.

Citeer dit